

WHERE HOMEBOUND PATIENTS BENEFIT FROM ONSITE TREATMENT, **WE GO**. WHERE LONG WAITS IN BUSY EMERGENCY ROOMS DO MORE HARM THAN GOOD, **WE GO**. WHERE UNDERSERVED POPULATIONS NEED BETTER CARE, **WE GO**. WHERE BASIC TELEHEALTH PROVIDERS STOP, **WE GO**. AND WHEN ALL REASON SAYS IT CAN'T BE DONE, LEAVE WELL ENOUGH ALONE AND QUIT WHILE YOU'RE AHEAD, WE DO WHAT OUR COMPANY HAS ALWAYS DONE. **WE GO**.



Investor Presentation



DISCLAIMER



Although the information contained herein is believed to be accurate, DocGo and each of its directors, officers, shareholders, members, partners and representatives, expressly disclaim liability for, and makes no expressed or implied representation or warranty with respect to, any information contained in or omitted from this presentation, or any other information or communication (whether written or oral) transmitted to any prospective investor. Only those representations and warranties made in a definitive agreement with any person shall have any legal effect.

This presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of DocGo, any company forming a part of DocGo or any of their respective affiliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Investors should make their own independent investigation of DocGo before investing in any securities.

PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

Use of Projections and Financial Information

This presentation contains financial forecasts relating to the anticipated future financial performance of DocGo and are subject to risks and uncertainties that could cause actual results to differ materially from those statements and should be read with caution. They are subjective in many respects and thus susceptible to interpretations and periodic revisions based on actual experience and recent developments. While presented with numerical specificity, the projections were not prepared in the ordinary course and are based upon a variety of estimates and hypothetical assumptions made by management of DocGo with respect to, among other things, general economic, market, interest rate and financial conditions, the availability and cost of capital for future investment, and competition within DocGo's markets. The projections were not prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for prospective financial information or generally accepted accounting principles in the United States of America ("GAAP").

None of the assumptions underlying the projections may be realized, and they are inherently subject to significant business, economic and competitive uncertainties and risks, all of which are difficult to predict and many of which are beyond the control of DocGo. Accordingly, there can be no assurance that the assumptions made in preparing the projections will prove accurate, and actual results may materially differ. Furthermore, while all projections are necessarily speculative, DocGo believes that prospective financial information covering periods beyond 12 months from its date of preparation carries increasingly higher levels of uncertainty and should be read in that context.

For these reasons, as well as the bases and assumptions on which the projections were compiled, the inclusion of the information set forth below should not be regarded as an indication that the projections will be an accurate prediction of future events, and they should not be relied on as such. Neither DocGo nor any of their respective affiliates, advisors or other representatives has made, or makes, any representation to any stockholder or prospective investor regarding the information contained in the projections and, except as required by applicable securities laws, DocGo does not intend to update or otherwise revise the projections to reflect circumstances existing after the date when made or to reflect the occurrences of future events even in the event that any or all of the assumptions are shown to be in error.

Non-GAAP Financial Information

This presentation also includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with GAAP, such as Earnings Before Interest, Tax, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA. As a result, such information may not conform to SEC Regulation S-X and may be adjusted and presented differently in filings with the SEC. Any non-GAAP financial measures used in this presentation are in addition to, and should not be considered superior to, or a substitute for, financial statements prepared in accordance with GAAP. DocGo has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this presentation that are calculated and presented in accordance with GAAP. Such non-GAAP financial measure should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this presentation. The non-GAAP financial measure in this presentation may differ from similarly titled measures used by other companies.

Market and Industry Data

Market data and industry data used throughout this presentation is based on information derived from third party sources, the knowledge of the management team of DocGo regarding its industries and businesses and respective management teams' good faith estimates. While management of DocGo believes that the third party sources from which market and industry data has been derived are reputable, DocGo has not independently verified such market and industry data, and you are cautioned not to give undue weight to such market and industry data.



DISCLAIMER (CON'T)

Forward Looking Statements

This presentation contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning DocGo. These statements include, but are not limited to, statements that address our expected future business and financial performance and statements about (i) our plans, objectives and intentions with respect to future operations, services and products, including our transition to non-COVID related services, geographic expansion, new and existing contracts and our “Zero Emission” initiative, (ii) our competitive position and opportunities, including our ability to realize the benefits from our operating model, and (iii) other statements identified by words such as “may”, “will”, “expect”, “intend”, “plan”, “potential”, “believe”, “seek”, “could”, “estimate”, “judgment”, “targeting”, “should”, “anticipate”, “predict” “project”, “aim”, “goal”, “outlook”, “guidance”, and similar words, phrases or expressions.

These forward-looking statements are based on management's current expectations and beliefs, as well as assumptions made by, and information currently available to, management, and current market trends and conditions. Forward-looking statements inherently involve risks and uncertainties, many of which are beyond our control, and which may cause actual results to differ materially from those contained in our forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect current or future results include possible accounting adjustments made in the process of finalizing reported financial results; any risks associated with global economic conditions and concerns; the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the COVID-19 coronavirus pandemic; competitive pressures; pricing declines; rates of growth in our target markets; our ability to improve gross margins; cost-containment measures; legislative and regulatory actions; the impact of legal proceedings and compliance risks; the impact on our business and reputation in the event of information technology system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; and the ability of the company to comply with laws and regulations regarding data privacy and protection. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in DocGo and is not intended to form the basis of an investment decision in DocGo. All subsequent written and oral forward-looking statements by DocGo, or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above.

Other Disclaimers

No representation or warranty, express or implied, can be made or is made by DocGo as to the accuracy or completeness of any such information. Except where otherwise indicated, this presentation speaks as of the date hereof and is necessarily based upon the information as of the date hereof, all of which are subject to change. DocGo has no obligation to update, bring-down, review or reaffirm this presentation. Under no circumstances should the delivery of this presentation imply that any information or analyses included in this presentation would be the same if made as of any other date. Nothing contained in this presentation is, or shall be relied upon as, a promise or representation as to the past, present or future.

This presentation provides summary information only and is being delivered solely for informational purposes. The recipient of this presentation acknowledges that:

DocGo does not provide legal, tax or accounting advice of any kind.

It is not relying on DocGo for legal, tax or accounting advice, and that the recipient should receive separate and qualified legal, tax and accounting advice in connection with any transaction or course of conduct.

Nothing contained herein shall be deemed to be a recommendation from DocGo to any party to enter into any transaction or to take any course of action.

This presentation is not intended to provide a basis for evaluating any transaction or other matter.

DocGo shall have no liability, whether direct or indirect, in contract or tort or otherwise, to any person in connection with this presentation.

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAS ANY REGULATORY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR SOLICITATION OF ANY SECURITIES.



DocGo: LEADING PROVIDER OF LAST MILE MOBILE HEALTHCARE



ABOUT DOCGO



- DocGo is a mobile health company that has provided service in 29 US states and across the UK
- The company brings healthcare services to patients where and when they need it – in the home, office or via mobile units in the field
- Delivery of both mobile health and medical transport services are managed logistically by DocGo's proprietary software platform supporting highly efficient and cost-effective delivery of healthcare
- Historically strong revenue growth, Q2 2023 revenues of \$125.5 million with \$9.1 million in Adjusted EBITDA^(a)
- Raised prior 2023 revenue guidance from \$500-\$510 million to \$540-\$550 million, Adjusted EBITDA^(a) from \$45-\$50 million to \$48-\$53 million



(a) Adjusted EBITDA is a non-GAAP measure, defined by DocGo as earnings before interest income, interest expense, taxes, depreciation, amortization, stock-based compensation, warrant revaluation and expenses related to DocGo's public listing.



CLINICAL DELIVERY OF DocGO SERVICES

- DocGo offers a wide variety of services from traditional EMS to mobile urgent care to higher acuity medical services
- Proven unit economic model utilizes lower-cost health care staff for onsite visits, with higher-cost APPs connected virtually via telehealth

Typical Services Utilized

- Chronic Care Management
- Episodic Care
- Primary/Preventive Care
- Inoculations
- Patient Transport
- Prescriptions
- Remote Patient Monitoring
- Urgent care
- **...and more**

On-Site Clinical Staff

- Certified Medical Assistant
- Emergency Medical Technician
- Licensed Practical Nurse
- Paramedic

Remote Clinical Staff

- Licensed Medical Physician
- Physician Assistant
- Nurse Practitioner
- Registered Nurse






Flexible, turnkey solution to patient care and recurring management



Formulaic usage of Healthcare professionals create efficiency with quality care



Common procedures executed at fraction of average industry cost



MOBILE HEALTH OFFERINGS

Tailored programs create value for key segments



Government (60% of revenues)

- Urgent care for low-income communities
- Migrant-related care programs
- Homeless shelter programs
- Street medicine programs



Payers (<10% of revenues)

- Care gap closure programs
- At-home urgent care
- Hospital readmission reduction programs
- Unnecessary ER visit program



Hospitals (30% of revenues)

- Pre/post-surgical program
- Emergency department readmission reduction program
- Remote patient monitoring



Events (<10% of revenues)

- Medical services at sports arenas
- Employee health at convention centers
- Medical standby at concerts and film shoots



DOC GO'S PROPRIETARY TECH PLATFORM

Comprehensive Solution for Mobile Health Care

2 min

EASY ORDERING

- Digital requesting via Web, Mobile, EMR integrations including Epic, and partner-ready APIs

100%


TOTAL TRANSPARENCY

- Integrated systems provide real-time updates to hospital staff, providers, patients, and family members

24/7

DIGITAL ACCESS

- Mobile Apps for patient to provider messaging and toll-free access to phone-based support



Modern Architecture and Design

EHR INTEGRATION

- Integrated with leading EHRs to enhance value and ease adoption of DocGo services



PROPRIETARY TECHNOLOGY & UX

- DocGo's technology platform and self-service UIs facilitate service delivery and results data
- Proprietary fleet management (CAD) system with AI-enabled routing and Google traffic integration

PATIENT-FACING MOBILE APP

- DocGo On-Demand for iOS & Android provides instant booking of health care visits, care team messaging, and access to results

SHARELINK™

- ShareLink™ technology provides hospitals, patients and their caregivers real-time vehicle location, accurate ETAs and peace of mind

HIPAA COMPLIANT & ISO 27001 CERTIFIED

- Designed for managing sensitive healthcare data, with application infrastructure certification

Our digital platform is integrated with industry standard EHRs and provides a seamless care logistics experience throughout the patient journey



ENGAGED CLINICIANS DELIVERING BETTER CARE

Thousands of highly trained clinicians

Mobile clinicians consisting of

- LPNs
- Paramedics
- EMTs
- RNs, PAs, NPs, MDs



Exceptional employee benefits including

- Competitive base pay
- Heavy investment in training
- Medical insurance
- Performance bonus
- 401(k)
- DocGo Employee Equity Incentive Program

- Improved patient care
- Improved employee NPS
- Improved loyalty to company
- Improved facility NPS
- Improved insurance rates

	indeed®	glassdoor®
DOC GO	4.3 ★★★★★	4.1 ★★★★★
one medical	3.2 ★★★★★	3.2 ★★★★★
dispatchhealth	2.7 ★★★★★	3.7 ★★★★★
OAK STREET HEALTH	2.5 ★★★★★	3.6 ★★★★★
Carbon Health	3.0 ★★★★★	3.5 ★★★★★

Ratings as of March 2023



A MODEL THAT BENEFITS THE ENTIRE HEALTHCARE ECOSYSTEM

Healthcare Professionals



- ✓ More satisfaction
- ✓ Better incentives

Providers



- ✓ Superior service
- ✓ Cost effective

Patients



- ✓ More convenient
- ✓ Better experience

Payers



- ✓ Lower cost
- ✓ Members access cost-effective care



SEGMENT OVERVIEW – MOBILE HEALTH

SUMMARY



- Mobile Health segment represents approximately 70% of revenues
- DocGo charges a fixed rate per day, per vehicle and per clinician, mitigating volume-based revenue and margin risk
- Contract terms tend to be one year with auto renew feature for municipal contracts, 2-3 years for state programs and 3+ years for federal contracts
- Significant customers include City of New York, Jefferson Health, Aetna and Fresenius Medical Care



TOTAL ADDRESSABLE MARKET
\$265 BILLION*

*US At Home Care. Sources: McKinsey “Telehealth: A quarter trillion-dollar post COVID-19 reality?” (report published 5/29/20), and, McKinsey “From facility to home: How healthcare could shift by 2025” (report published February 2022)



SEGMENT OVERVIEW – MEDICAL TRANSPORTATION

SUMMARY



- Medical Transportation represents approximately 30% of revenues
- Providing non-emergency medical transport between clinical settings and/or patient's residences
- Leased hour pricing model provides greater financial predictability, approximately \$1,500 per day for a dedicated two-person crew and ambulance
- Combination of cash pay and Insurance/Medicare/Medicaid
- Transitioning legacy “fee for service” contracts to more lucrative leased hour contracts
- Gross Margin target of 30%+
- Major customers include NYC Health + Hospitals, Northwell and HCA



TOTAL ADDRESSABLE MARKET
\$7-\$13 BILLION*

*Source: US, Ambulance Only. Management estimates.



ILLUSTRATIVE CUSTOMERS, PARTNERS & PROJECTS

Leading health systems, payers, corporations and municipalities



England




OUR FOOTPRINT AND REACH



DocGo has provided services in **29 US states** and the **UK**

Authorized to provide clinical services in 38 states

<1% market penetration today



COMPETITIVE MOAT



DocGo has continued to expand its moat, preserving its value proposition by relying on technology to efficiently deploy our resources. The formulaic balance of AI and human specialty has improved DocGo's unit economics, positioning us to disrupt both our competitors and the healthcare market overall.



PILOT PROGRAMS

- DocGo is partnering with household brands to provide on-demand care to patients where and when they need it, all done outside the traditional four walls of the medical establishment
- Looking to leverage our technology & reach, companies all over are looking to initiate innovative partnerships that utilize co-branding techniques for patient care across the map

**DOLLAR
GENERAL**

Dollar General

- Limited pilot program providing basic primary and urgent care to select Dollar General locations
- Dollar General has 19,000 locations in the US, 70% of which are attractive prospects
- One unit rotates across three stores
- Urgent care type reimbursement model

DocGo On-Demand

- Providing primary and urgent care type services at select locations in the Northeast
- Over 4,700 patient interactions to date - accumulating data to study unit economics
- Transformative proposition to consumers in need of routine care

Insurance Companies

- Contracted to provide urgent care and preventative health care services to five major insurance companies, primarily in the Northeast including Aetna, Cigna and Horizon BCBS
- Covering approximately 10M lives
- Ability to scale nationally if programs demonstrate success


Remote Patient Monitoring

- Partnered with West Pace in San Diego to remotely monitor at-risk senior populations
- When outside parameters, DocGo can provide home visits to remedy and avoid costly ER admissions
- Collect data to support the unit economic model for both DocGo and payers



Q2 2023 FINANCIAL UPDATE

(\$ in millions)



- Excluding mass COVID-testing revenue (<\$1.0 million per quarter in 2023), revenues grew 53% Y/Y

Q2 2023 Financial Highlights

- Total Q1 2023 revenue was \$125.5 million, as compared to \$109.5 for the comparable period in 2022.
- Adjusted EBITDA was \$9.1 million
- Mobile Health revenue for Q2 2023 was \$80.1 million as compared to \$87.3 million for Q1 2022. Excluding mass COVID testing revenue from both periods, Mobile Health revenue increased ~33% as compared to Q2 2022.
- Transportation Services revenue was \$45.4 million compared to \$22.2 million for Q2 2022, an increase of ~105%

Q2 2023 Business Highlights

- Launched multiple new care gap closure programs with four major payers.
- Signed a contract with NYC DHPD (not to exceed \$432 million) for primary care and other supporting services to migrant populations in New York.
- Launched Dara Transport Network integrated digital brokering platform.
- Awarded *Best Overall Mobile Health Solution* (with New York City Health + Hospitals) for Street Health Outreach + Wellness program.
- Announced strategic mobile health agreement with Fresenius Medical Care and launched a suite of services designed to help nephrologists better manage the ~780,000 end-stage renal disease patients and millions of chronic kidney disease patients currently estimated to reside in the U.S.



GROWTH DRIVERS FOR 2023

DocGo's growth strategy will be fueled by the following key components

Legacy Customers	<ul style="list-style-type: none">▪ Continue expansion of existing customers with 3, 4, 5th generation contracts
Mobile Health Pilots	<ul style="list-style-type: none">▪ Build on the success of On-Demand, expand offering and footprint
Payer Pilot	<ul style="list-style-type: none">▪ Mobile Urgent Care service continues to gain network coverage for premier payers
Remote Patient Monitoring	<ul style="list-style-type: none">▪ 'Total RPM' being surveyed by large RPM software solutions for patient support
RFP Channel	<ul style="list-style-type: none">▪ Large federal and state-level opportunities represent multi-million-dollar deals
M&A Channel	<ul style="list-style-type: none">▪ Disciplined M&A approach will continue to gain access to new services and regions



EXPERIENCED LEADERSHIP TEAM

Stan Vashovsky
Co-Founder,
Non-Executive Chairman of the Board



- Founded DocGo (f/k/a Ambulnz) in 2015 with the vision to revolutionize medical transportation and healthcare delivery
- Previously executive for services innovations at Philips Healthcare
- 25+ years of healthcare experience including paramedic work

Lee Bienstock
Chief Executive Officer




- Joined DocGo in March 2022 as Chief Operating Officer
- Promoted to President in January 2023, and CEO in September 2023
- Spent 10 years at Google, where he most recently served as Global Head of Enterprise Partnerships for Devices & Services
- MBA from the Wharton School of Business

Norm Rosenberg
Treasurer & Chief Financial Officer



- Joined DocGo in January 2020 as CFO of Ambulnz Holdings, LLC
- Promoted to CFO in January 2023, and Treasurer in September 2023
- More than 20 years experience as CFO in various companies including telecom and insurance industries


Andre Oberholzer
EVP of Strategy




Ely Tendler
General Counsel




Stephen Sugrue
Chief Compliance Officer




Rosemarie Milano
VP, Human Resources



Dr. James Powell
CEO, Clinical Practice Group



Kevin Bland
VP, Operations




KEY TAKEAWAYS

- ➔ Rapid revenue growth, nine quarters of positive adjusted EBITDA, history of beating revenue expectations and raising guidance
- ➔ Significant market and growth opportunity with limited competition
- ➔ Early stages of accelerating recurring revenue growth
- ➔ Unique value proposition to healthcare systems and patients
- ➔ Defensible competitive technology advantage
- ➔ Highly attractive customer base
- ➔ Mission-driven company with experienced management team

